Literature DB >> 15179554

Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.

Robert A Figlin1, H Alvin, C L Meinhardt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15179554     DOI: 10.1007/s00120-004-0607-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  4 in total

1.  Mathematical model to predict individual survival for patients with renal cell carcinoma.

Authors:  Amnon Zisman; Allan J Pantuck; Fredrick Dorey; Debby H Chao; Barbara J Gitlitz; Nancy Moldawer; Dana Lazarovici; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

2.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.

Authors:  Matthew H T Bui; David Seligson; Ken-ryu Han; Allan J Pantuck; Frederick J Dorey; Yunda Huang; Steve Horvath; Bradley C Leibovich; Shefali Chopra; Shu-Yuan Liao; Eric Stanbridge; Michael I Lerman; Aarno Palotie; Robert A Figlin; Arie S Belldegrun
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

3.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

Review 4.  Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.

Authors:  Allan J Pantuck; Gang Zeng; Arie S Belldegrun; Robert A Figlin
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.